首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   217024篇
  免费   12712篇
  国内免费   544篇
耳鼻咽喉   2784篇
儿科学   7218篇
妇产科学   4818篇
基础医学   29335篇
口腔科学   8402篇
临床医学   19100篇
内科学   47298篇
皮肤病学   5226篇
神经病学   18506篇
特种医学   6214篇
外国民族医学   26篇
外科学   25898篇
综合类   1819篇
现状与发展   1篇
一般理论   118篇
预防医学   23212篇
眼科学   3843篇
药学   12947篇
中国医学   792篇
肿瘤学   12723篇
  2023年   1121篇
  2022年   2386篇
  2021年   4598篇
  2020年   3007篇
  2019年   4512篇
  2018年   6025篇
  2017年   4454篇
  2016年   4219篇
  2015年   4976篇
  2014年   6838篇
  2013年   8961篇
  2012年   13741篇
  2011年   14503篇
  2010年   7506篇
  2009年   6681篇
  2008年   11635篇
  2007年   12304篇
  2006年   11666篇
  2005年   11752篇
  2004年   11152篇
  2003年   10290篇
  2002年   8186篇
  2001年   5639篇
  2000年   5619篇
  1999年   5040篇
  1998年   2065篇
  1997年   1731篇
  1996年   1686篇
  1995年   1422篇
  1994年   1385篇
  1993年   1282篇
  1992年   3024篇
  1991年   2854篇
  1990年   2625篇
  1989年   2599篇
  1988年   2286篇
  1987年   2146篇
  1986年   1980篇
  1985年   1928篇
  1984年   1470篇
  1983年   1211篇
  1982年   788篇
  1981年   702篇
  1980年   675篇
  1979年   1056篇
  1978年   707篇
  1977年   570篇
  1975年   634篇
  1974年   637篇
  1973年   633篇
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
Introduction: The landscape of poly (ADP-ribose) polymerase (PARP) inhibition in ovarian cancer is rapidly evolving and becoming increasingly complex. Ovarian cancer is leading therapeutic innovation by providing the proof of concept for DNA repair as a target. Three different PARP inhibitors have now received approvals in the US and Europe in different indications. Subtle but crucial differences can be found among the licensed indications for each PARP inhibitor in terms of histology, type of BRCA mutation (germline and/or somatic), number of prior lines of chemotherapy and whether the indication is in the treatment or maintenance settings.

Areas covered: We review the latest clinical data regarding the PARP inhibitor rucaparib in ovarian cancer, provide an update on the evolving landscape of PARP inhibition in ovarian cancer, and summarize avenues of ongoing and future research.

Expert opinion: All eligible patients should be offered a PARP inhibitor. SOLO1 trial results demonstrated an unprecedented benefit maintenance with PARP inhibitors in first line. Results from trials evaluating PARP inhibitors as maintenance in first line regardless of BRCA status and from trials evaluating combinatorial strategies are eagerly awaited.  相似文献   

2.
Neorickettsia helminthoeca (NH), the agent of salmon poisoning disease or canine neorickettiosis (CN), is a bacterial endosymbiont of the nematode Nanophyetus salmincola, and infections are spreading among specific fish‐eating mammalians. This article describes the pathologic and immunohistochemical findings associated with spontaneous NH‐induced infections in dogs from Southern Brazil. The principal pathologic findings were hypertrophy of Peyer patches and lymphadenopathy with lymphocytic proliferation, chronic interstitial pneumonia, and chronic enteritis associated with positive intralesional immunoreactivity to antigens of NH within macrophages and histiocytes. Positive immunoreactivity against canine parvovirus‐2 (CPV‐2) or/and canine distemper virus was not detected in the evaluated intestinal segments or in the samples from the cerebellum and lungs, respectively, from the dogs evaluated. These findings demonstrated that NH was involved in the enteric, pulmonary, and lymphoid lesions herein described, and provide additional information to confirm the occurrence of this bacterial endosymbiont within this geographical location. It is proposed that chronic pneumonia should be considered as a pathologic manifestation of NH‐induced infections. Additionally, our results show that the occurrences of CN seem to be underdiagnosed in Southern Brazil due to the confusion with the incidence of CPV‐2.  相似文献   
3.
4.
5.
6.
7.
8.
9.
10.
Objective: Polyunsaturated fatty acids n-3 (PUFA n-3) have shown effects in reducing tumor growth, in particular eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) abundantly present in fish oil (FO). When these fatty acids are provided in the diet, they alter the functions of the cells, particularly in tumor and immune cells. However, the effects of α-linolenic fatty acid (ALA), which is the precursor of EPA and DHA, are controversial. Thus, our objective was to test the effect of this parental fatty acid. Methods: Non-tumor-bearing and tumor-bearing Wistar rats (70 days) were supplemented with 1 g/kg body weight of FO or Oro Inca® (OI) oil (rich in ALA). Immune cells function, proliferation, cytokine production, and subpopulation profile were evaluated. Results: We have shown that innate immune cells enhanced phagocytosis capacity, and increased processing and elimination of antigens. Moreover, there was a decrease in production of pro-inflammatory cytokines (tumor necrosis factor-alpha (TNF-α) and interleukin 6 (IL-6)) by macrophages. Lymphocytes showed decreased proliferation capacity, increased cluster of differentiation 8 (CD8+) subpopulation, and increased TNF-α production. Conclusions: Oil rich in ALA caused similar immune modulation in cancer when compared with FO.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号